Mr. Thiago JordĆ£o S Lemos | Nanobiotechnology Awards | NanoHealth Innovator Prize

Mr. Thiago JordĆ£o S Lemos | Nanobiotechnology Awards | NanoHealth Innovator Prize

Mr. Thiago JordĆ£o S Lemos , Instituto Butantan , Brazil

Thiago JordĆ£o da Silva Lemos is a biomedical researcher currently affiliated with the Butantan Institute in SĆ£o Paulo, Brazil. He earned his degree in Biomedicine from Universidade Paulista (UNIP) and has extensive experience in research and development, particularly in immunology and animal health. He completed a postgraduate program at the Butantan Institute, focusing on microbiology, where he investigated the immune response induced by an oral vaccine against E. coli serogroups O26 and O111. Lemos has also held roles as a nursing technician and assistant and participated in a short-term internship at the Biophysics Institute of the Federal University of Rio de Janeiro (UFRJ). His research interests include vaccine development and infectious diseases, and he is actively involved in evaluating immune responses to pathogens in order to develop effective vaccines.

Professional Profile:

Orcid

Ā šŸŽ“Education:

Thiago JordĆ£o da Silva Lemos earned his degree in Biomedicine from Universidade Paulista (UNIP), Brazil, with a thesis titled “Frequency of Bovine Viral Diarrhea in the State of SĆ£o Paulo,” under the guidance of Ediviges Maristela Pituco. He further pursued postgraduate studies at the Butantan Institute, focusing on microbiology, where he researched the immune response induced by an oral vaccine against E. coli serogroups O26 and O111. Additionally, Lemos completed a short-term internship at the Biophysics Institute of the Federal University of Rio de Janeiro (UFRJ)

Ā šŸ¢Work Experience:

Lemos is currently affiliated with the Butantan Institute in SĆ£o Paulo, Brazil, where he works on evaluating immune responses to pathogens to develop effective vaccines. He has held roles as a nursing technician and assistant and has been a member of a research team investigating the immune response induced by an oral vaccine against E. coli serogroups O26 and O111. His professional experience encompasses research and development in immunology and animal health, with a focus on vaccine development and infectious diseases.

Publication Top Notes:

  • O26 Polysaccharides as Key Players in Enteropathogenic E. coli Immune Evasion and Vaccine Development
    • Journal: International Journal of Molecular Sciences
    • Publication Date: 2024-03-01
  • Characterization of O26 Enteropathogenic E. coli and Its Implication for Vaccine Development
    • Publication Date: 2023-12-19
  • The potential of Loxosceles gaucho spider venom to regulate Pseudomonas aeruginosa mechanisms of virulence
    • Journal: Toxicon
    • Publication Date: 2018
  • Potential influence of bacterial biofilm formation on scalp folliculitis therapy